Thera-SAbDab

CANAKINUMAB

>   Structural Summary
TherapeuticCanakinumab
TargetIL1B
Heavy ChainQVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS
Light ChainEIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK
100% seqID Fv StructureNone
99% seqID Fv Structure4g5z [Fvs: HL], 4g6j [Fvs: HL], 5bvj [Fvs: BA, DC, FE, HG], 5bvp [Fvs: HL]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Canakinumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 101 102 103 104 105 106 107 108 109 110 111 112 113
canakinumab Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S V Y G M N W V R Q A P G K G L E W V A I I W Y D G D N Q Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N G L R A E D T A V Y Y C A R D L R T G P F D Y W G Q G T L V T V S S
5bvp E V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S V Y G M N W V R Q A P G K G L E W V A I I W Y D G D N Q Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N G L R A E D T A V Y Y C A R D L R T G P F D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
canakinumab E I V L T Q S P D F Q S V T P K E K V T I T C R A S Q S I G S S L H W Y Q Q K P D Q S P K L L I K Y A S Q S F S G V P S R F S G S G S G T D F T L T I N S L E A E D A A A Y Y C H Q S S S L P F T F G P G T K V D I K
5bvp E I V L T Q S P D F Q S V T P K E K V T I T C R A S Q S I G S S L H W Y Q Q K P D Q S P K L L I K Y A S Q S F S G V P S R F S G S G S G T D F T L T I N S L E A E D A A A Y Y C H Q S S S L P F T F G P G T K V D I K
Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 101 102 103 104 105 106 107 108 109 110 111 112 113
canakinumab Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S V Y G M N W V R Q A P G K G L E W V A I I W Y D G D N Q Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N G L R A E D T A V Y Y C A R D L R T G P F D Y W G Q G T L V T V S S
5bvj E V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S V Y G M N W V R Q A P G K G L E W V A I I W Y D G D N Q Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N G L R A E D T A V Y Y C A R D L R T G P F D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
canakinumab E I V L T Q S P D F Q S V T P K E K V T I T C R A S Q S I G S S L H W Y Q Q K P D Q S P K L L I K Y A S Q S F S G V P S R F S G S G S G T D F T L T I N S L E A E D A A A Y Y C H Q S S S L P F T F G P G T K V D I K
5bvj E I V L T Q S P D F Q S V T P K E K V T I T C R A S Q S I G S S L H W Y Q Q K P D Q S P K L L I K Y A S Q S F S G V P S R F S G S G S G T D F T L T I N S L E A E D A A A Y Y C H Q S S S L P F T F G P G T K V D I K
Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 101 102 103 104 105 106 107 108 109 110 111 112 113
canakinumab Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S V Y G M N W V R Q A P G K G L E W V A I I W Y D G D N Q Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N G L R A E D T A V Y Y C A R D L R T G P F D Y W G Q G T L V T V S S
4g6j Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S V Y G M N W V R Q A P A K G L E W V A I I W Y D G D N Q Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N G L R A E D T A V Y Y C A R D L R T G P F D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
canakinumab E I V L T Q S P D F Q S V T P K E K V T I T C R A S Q S I G S S L H W Y Q Q K P D Q S P K L L I K Y A S Q S F S G V P S R F S G S G S G T D F T L T I N S L E A E D A A A Y Y C H Q S S S L P F T F G P G T K V D I K
4g6j E I V L T Q S P D F Q S V T P K E K V T I T C R A S Q S I G S S L H W Y Q Q K P D Q S P K L L I K Y A S Q S F S G V P S R F S G S G S G T D F T L T I N S L E A E D A A A Y Y C H Q S S S L P F T F G P G T K V D I K
Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 101 102 103 104 105 106 107 108 109 110 111 112 113
canakinumab Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S V Y G M N W V R Q A P G K G L E W V A I I W Y D G D N Q Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N G L R A E D T A V Y Y C A R D L R T G P F D Y W G Q G T L V T V S S
4g5z Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S V Y G M N W V R Q A P A K G L E W V A I I W Y D G D N Q Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N G L R A E D T A V Y Y C A R D L R T G P F D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
canakinumab E I V L T Q S P D F Q S V T P K E K V T I T C R A S Q S I G S S L H W Y Q Q K P D Q S P K L L I K Y A S Q S F S G V P S R F S G S G S G T D F T L T I N S L E A E D A A A Y Y C H Q S S S L P F T F G P G T K V D I K
4g5z E I V L T Q S P D F Q S V T P K E K V T I T C R A S Q S I G S S L H W Y Q Q K P D Q S P K L L I K Y A S Q S F S G V P S R F S G S G S G T D F T L T I N S L E A E D A A A Y Y C H Q S S S L P F T F G P G T K V D I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyMedarex UltiMAb Mouse
INN Year Proposed2007
INN Year Recommended2008
Companies InvolvedCharite - Universitatsmedizin Berlin, Novartis, Triemli hospital, University Hospital Tubingen, University Hospital Zurich
Conditions ApprovedAdult-onset Still's disease, Cryopyrin-associated periodic syndromes, Familial autosomal dominant periodic fever, Familial Mediterranean fever, Gouty arthritis, Juvenile rheumatoid arthritis, Peroxisomal disorders
Conditions ActiveCardiovascular disorders, Behcet's syndrome, Non-small cell lung cancer, Abdominal aortic aneurysm, Atherosclerosis, Malignant melanoma, Osteoarthritis, Peripheral arterial occlusive disorders, Pulmonary sarcoidosis, Schnitzler syndrome, Sickle cell anaemia, Breast cancer
Conditions DiscontinuedChronic obstructive pulmonary disease, Asthma, Diabetic retinopathy, Polymyalgia rheumatica, Rheumatoid arthritis, Type 1 diabetes mellitus, Type 2 diabetes mellitus
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]